Back to Insights

What impact is Biogen’s Aduhelm (aducanumab) likely to have on the Alzheimer’s Market?

Posted by Varun Renjen, M.D. on June 24th, 2021.

On June 7, 2021, the FDA approved Biogen’s Aduhelm® (aducanumab) for Alzheimer’s disease.  As the first potentially disease-modifying therapy for Alzheimer’s, it could have some significant impacts on the market for Alzheimer’s therapies.

Varun Renjen, M.D., outlines those potential impacts in this short video.

Link here